Case Studies

The following are examples of Apredica's high value-added approach towards solving our clients' ADME Tox issues.

• Custom Assay Development
  A compound was found to have a potential side effect - shortly before a board meeting.



• Initial ADMET Screen
  For a discovery program with novel structures potential ADMET problems to be addressed by the medicinal chemistry program needed to be identified.



• Clinical Candidate Selection
  Six chemical series of compounds with excellent efficacy profiles had been identified. Which should be prioritized for preclinical studies?



• In Vivo Efficacy
  Unexpected bioanalytical results were obtained in clinical trials. The parent compound disappeared rapidly in plasma. The metabolic pathway of the compound was unknown. Pharmacokinetic studies were compromised by ex vivo metabolism of the compound.
  
  

Contact us to learn more about how Apredica can advance your drug-discovery program.